Curis (CRIS) Accounts Payables (2010 - 2026)
Curis' (CRIS) quarterly Accounts Payables came in at $5.4 million in Q2 2026, up 31.51% on a YoY basis from $4.1 million in Q2 2025, and down 20.08% quarter-over-quarter from $6.7 million in Q1 2026.
Analysis
Curis (CRIS) Accounts Payables (2010 - 2026) Analysis & Trends
Curis (CRIS) has reported Accounts Payables for 17 consecutive years, with $5.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Accounts Payables rose 31.51% year-over-year to $5.4 million; the trailing twelve-month figure through Jun 2026 stood at $5.4 million (up 31.51% YoY), and the FY2025 full-year result was $5.6 million, up 85.58% from the prior year.
- Accounts Payables declined to $5.4 million in Q2 2026 per CRIS's latest filing, from $6.7 million in the prior quarter.
- Across five years, Accounts Payables topped out at $6.7 million in Q1 2026 and bottomed at $2.4 million in Q2 2024.
- Historically, Accounts Payables has averaged $4.3 million across 5 years, with a median of $4.2 million in 2022.
- The sharpest annual moves came in 2023 and 2025: Accounts Payables slumped 51.26% in 2023, then surged 85.58% in 2025.
- Over 5 years, Accounts Payables stood at $3.2 million in 2022, then fell by 0.66% to $3.2 million in 2023, then dropped by 4.67% to $3.0 million in 2024, then soared by 85.58% to $5.6 million in 2025, then decreased by 3.99% to $5.4 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $5.4 million, $6.7 million, and $5.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 2.87 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 674.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 429.50 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.16 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 167.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 403.90 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Curis | 2.63 Mn | -2.99 Mn | - | 5.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.39 Mn |
| Mar 31, 2026 | 6.74 Mn |
| Dec 31, 2025 | 5.61 Mn |
| Sep 30, 2025 | 4.45 Mn |
| Jun 30, 2025 | 4.10 Mn |
| Mar 31, 2025 | 5.10 Mn |
| Dec 31, 2024 | 3.02 Mn |
| Sep 30, 2024 | 3.82 Mn |
| Jun 30, 2024 | 2.45 Mn |
| Mar 31, 2024 | 3.63 Mn |
| Dec 31, 2023 | 3.17 Mn |
| Sep 30, 2023 | 5.22 Mn |
| Jun 30, 2023 | 2.69 Mn |
| Mar 31, 2023 | 2.64 Mn |
| Dec 31, 2022 | 3.19 Mn |
| Sep 30, 2022 | 5.76 Mn |
| Jun 30, 2022 | 5.51 Mn |
| Mar 31, 2022 | 4.28 Mn |
| Dec 31, 2021 | 6.42 Mn |
| Sep 30, 2021 | 3.51 Mn |